Survey
Quarterly Survey: Narcolepsy Oxybate Treatments and Avadel’s Lumryz October 2023
Ticker(s): AVDL, JAZZThe survey results include 20 physicians that treat Narcolepsy.
How many patients with Narcolepsy are under your care?
How many patients with Narcolepsy do you have on an Oxybate drug (Xyrem, Xywav, Lumryz) right now?
How many patients are currently on the following treatments?:
- Xyrem branded
- Xyrem generic
- Xywav
- Lumryz
Of the [X] patients you currently have on Lumryz, how many of them:
- Are switches from Xyrem/Xywav?
- Are new Oxybate starts?
How many patients have you enrolled in the Ryzup program so far?
What percentage (%) of patients who initially enroll in the RYRUP program do you expect to ultimately not follow through or decide not to get put on Lumryz? Please indicate "NA" if you do not know.
What is the median time (in weeks) that it takes for a patient to start Lumryz after you initially send them to Ryzup? Please indicate "NA" if you do not know.
What percentage (%) of your Oxybate patients have proactively/independently reached out to discuss Lumryz with you?
Please describe patient satisfaction with Lumryz (after patients have initiated treatment and completed titration) compared to Xyrem or Xywav?
Of the existing patients you currently have on Xyrem or Xywav, how many do you expect to switch to Lumryz over the next 12 months?
How many patients do you expect to have on Lumryz at the following points in time (please factor new starts, switches, and drops):
- December 31, 2023
- March 31, 2024
- June 30, 2024
- December 31, 2024
Please comment on how your patient experience with Lumryz has been so far, and describe if there have been any surprises (good or bad) relative to what you expected? Please be specific.
Looking ahead to new Oxybate starts in the next year, what percentage (%) do you expect to end up on Lumryz?
Do you think having a 1x nightly dosing option with Lumryz will significantly increase the overall use of oxybate treatments in your practice? Why or why not? Please be specific.
What percent (%) do you expect the overall oxybate population in your practice to grow, if at all, at the following timepoints:
Please elaborate on your view of Lumryz. Please be specific.
On a scale 1-10 (where 1 is low and 10 is high) how excited are you about the potential benefits of Lumryz for your patients with narcolepsy?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
